Comparison of two combined drug therapy regimens for renal damage in patients with metastatic kidney cancer after previously performed unilateral nephrectomy
Relevance. Almost 450 new cases of renal cell carcinoma and almost 160 deaths from cancer are detected annually. Of particular interest to patients with metastatic renal cell carcinoma who often undergo radical nephrectomy prior to the appointment of combined immunotherapy is the assessment of furth...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Private institution educational organization of higher education "Medical University "ReaViz"
2025-06-01
|
| Series: | Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье |
| Subjects: | |
| Online Access: | https://vestnik.reaviz.ru/jour/article/view/1170 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849402662872678400 |
|---|---|
| author | K. S. Titov M. V. Epifanova A. A. Alimov O. Yu. Nesterova E. V. Shutov S. S. Lebedev G. M. Zapirov |
| author_facet | K. S. Titov M. V. Epifanova A. A. Alimov O. Yu. Nesterova E. V. Shutov S. S. Lebedev G. M. Zapirov |
| author_sort | K. S. Titov |
| collection | DOAJ |
| description | Relevance. Almost 450 new cases of renal cell carcinoma and almost 160 deaths from cancer are detected annually. Of particular interest to patients with metastatic renal cell carcinoma who often undergo radical nephrectomy prior to the appointment of combined immunotherapy is the assessment of further renal damage that occurs while taking tyrosine kinase inhibitors and immune checkpoint blockers.Objective: to compare renal damage in patients with metastatic RCC with a single kidney taking two drug therapy regimens: ipilimumab + nivolumab and pembrolizumab + axitinib. Object and methods. A retrospective study included 100 patients (73% men and 27% women) with metastatic renal cell carcinoma of the unfavorable prognosis group who had previously undergone unilateral radical nephrectomy for the underlying disease. 50 patients received ipilimumab + nivolubab combined immunotherapy, while 50 patients received pembrolizumab + axitinib. In these groups, CKD was observed in 83.0% and 77.3% of patients, respectively (80.2% of the total sample). Patients receiving pembrolizumab + axitinib were slightly older (median 63.0 years and 57.0 years, p = 0.019).Damage to a single kidney was assessed during 28-36 weeks of combination therapy, which corresponded to 12 drug injections in each group.Results. Acute renal injury (AKI) after the 1st administration of ipilimumab + nivolumab was observed in 10%, while after the 1st administration of pembrolizumao + axitinib - in 11% (p = 1,000). The maximum difference in AKI between the studied groups was noted after the 10th administration: AKI occurred in 25% and 6% of cases in the groups of patients receiving ipilimumab + nivolumab and pembrolizumab + axitinib, respectively, but the differences were also statistically insignificant (p = 0.513). Despite the older age of patients receiving pembrolizumab + axitinib, the average creatinine in the ipilimumab + nivolumab group was 43.0 mmol/L higher than in patients in the pembrolizumab + axitinib group (p < 0.001). Over the entire duration of therapy, urea in the ipilimumab + nivolumab group was 1.7 mmol/L higher (p = 0.010) than in the pembrolizumab + axitinib group with initially comparable parameters. The maximum difference in urea between the groups was observed after the 5th and 12th administration of the drugs, amounting to 2.6 mmol/l and 2.7 mmol/l, respectively (p = 0.009 and p = 0.032, respectively).Conclusion. Combined immunotherapy with ipilimumab + nivolumab in patients with metastatic RCC in patients with a single kidney has a more pronounced deterioration in renal function compared with combined immunotherapy with pembrolizumab + axitinib. |
| format | Article |
| id | doaj-art-e33eafa668c44836867e950093a4c92c |
| institution | Kabale University |
| issn | 2226-762X 2782-1579 |
| language | Russian |
| publishDate | 2025-06-01 |
| publisher | Private institution educational organization of higher education "Medical University "ReaViz" |
| record_format | Article |
| series | Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье |
| spelling | doaj-art-e33eafa668c44836867e950093a4c92c2025-08-20T03:37:29ZrusPrivate institution educational organization of higher education "Medical University "ReaViz"Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье2226-762X2782-15792025-06-01152687710.20340/vmi-rvz.2025.2.CLIN.2721Comparison of two combined drug therapy regimens for renal damage in patients with metastatic kidney cancer after previously performed unilateral nephrectomyK. S. Titov0M. V. Epifanova1A. A. Alimov2O. Yu. Nesterova3E. V. Shutov4S. S. Lebedev5G. M. Zapirov6Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin; Patrice Lumumba Peoples' Friendship University of RussiaPatrice Lumumba Peoples' Friendship University of RussiaMoscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin; Patrice Lumumba Peoples' Friendship University of RussiaLomonosov Moscow State UniversityMoscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin; Russian Medical Academy of Continuous Professional EducationMoscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin; Russian Medical Academy of Continuous Professional EducationPatrice Lumumba Peoples' Friendship University of RussiaRelevance. Almost 450 new cases of renal cell carcinoma and almost 160 deaths from cancer are detected annually. Of particular interest to patients with metastatic renal cell carcinoma who often undergo radical nephrectomy prior to the appointment of combined immunotherapy is the assessment of further renal damage that occurs while taking tyrosine kinase inhibitors and immune checkpoint blockers.Objective: to compare renal damage in patients with metastatic RCC with a single kidney taking two drug therapy regimens: ipilimumab + nivolumab and pembrolizumab + axitinib. Object and methods. A retrospective study included 100 patients (73% men and 27% women) with metastatic renal cell carcinoma of the unfavorable prognosis group who had previously undergone unilateral radical nephrectomy for the underlying disease. 50 patients received ipilimumab + nivolubab combined immunotherapy, while 50 patients received pembrolizumab + axitinib. In these groups, CKD was observed in 83.0% and 77.3% of patients, respectively (80.2% of the total sample). Patients receiving pembrolizumab + axitinib were slightly older (median 63.0 years and 57.0 years, p = 0.019).Damage to a single kidney was assessed during 28-36 weeks of combination therapy, which corresponded to 12 drug injections in each group.Results. Acute renal injury (AKI) after the 1st administration of ipilimumab + nivolumab was observed in 10%, while after the 1st administration of pembrolizumao + axitinib - in 11% (p = 1,000). The maximum difference in AKI between the studied groups was noted after the 10th administration: AKI occurred in 25% and 6% of cases in the groups of patients receiving ipilimumab + nivolumab and pembrolizumab + axitinib, respectively, but the differences were also statistically insignificant (p = 0.513). Despite the older age of patients receiving pembrolizumab + axitinib, the average creatinine in the ipilimumab + nivolumab group was 43.0 mmol/L higher than in patients in the pembrolizumab + axitinib group (p < 0.001). Over the entire duration of therapy, urea in the ipilimumab + nivolumab group was 1.7 mmol/L higher (p = 0.010) than in the pembrolizumab + axitinib group with initially comparable parameters. The maximum difference in urea between the groups was observed after the 5th and 12th administration of the drugs, amounting to 2.6 mmol/l and 2.7 mmol/l, respectively (p = 0.009 and p = 0.032, respectively).Conclusion. Combined immunotherapy with ipilimumab + nivolumab in patients with metastatic RCC in patients with a single kidney has a more pronounced deterioration in renal function compared with combined immunotherapy with pembrolizumab + axitinib.https://vestnik.reaviz.ru/jour/article/view/1170metastatic renal cell carcinoma [c04.588.945.947.408]combination drug therapy [e02.319.267]nephrotoxicity [c12.777.419.825]unilateral nephrectomy [e04.555.940]renal injury [c12.777.419.825]comparative study [v03.175] |
| spellingShingle | K. S. Titov M. V. Epifanova A. A. Alimov O. Yu. Nesterova E. V. Shutov S. S. Lebedev G. M. Zapirov Comparison of two combined drug therapy regimens for renal damage in patients with metastatic kidney cancer after previously performed unilateral nephrectomy Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье metastatic renal cell carcinoma [c04.588.945.947.408] combination drug therapy [e02.319.267] nephrotoxicity [c12.777.419.825] unilateral nephrectomy [e04.555.940] renal injury [c12.777.419.825] comparative study [v03.175] |
| title | Comparison of two combined drug therapy regimens for renal damage in patients with metastatic kidney cancer after previously performed unilateral nephrectomy |
| title_full | Comparison of two combined drug therapy regimens for renal damage in patients with metastatic kidney cancer after previously performed unilateral nephrectomy |
| title_fullStr | Comparison of two combined drug therapy regimens for renal damage in patients with metastatic kidney cancer after previously performed unilateral nephrectomy |
| title_full_unstemmed | Comparison of two combined drug therapy regimens for renal damage in patients with metastatic kidney cancer after previously performed unilateral nephrectomy |
| title_short | Comparison of two combined drug therapy regimens for renal damage in patients with metastatic kidney cancer after previously performed unilateral nephrectomy |
| title_sort | comparison of two combined drug therapy regimens for renal damage in patients with metastatic kidney cancer after previously performed unilateral nephrectomy |
| topic | metastatic renal cell carcinoma [c04.588.945.947.408] combination drug therapy [e02.319.267] nephrotoxicity [c12.777.419.825] unilateral nephrectomy [e04.555.940] renal injury [c12.777.419.825] comparative study [v03.175] |
| url | https://vestnik.reaviz.ru/jour/article/view/1170 |
| work_keys_str_mv | AT kstitov comparisonoftwocombineddrugtherapyregimensforrenaldamageinpatientswithmetastatickidneycancerafterpreviouslyperformedunilateralnephrectomy AT mvepifanova comparisonoftwocombineddrugtherapyregimensforrenaldamageinpatientswithmetastatickidneycancerafterpreviouslyperformedunilateralnephrectomy AT aaalimov comparisonoftwocombineddrugtherapyregimensforrenaldamageinpatientswithmetastatickidneycancerafterpreviouslyperformedunilateralnephrectomy AT oyunesterova comparisonoftwocombineddrugtherapyregimensforrenaldamageinpatientswithmetastatickidneycancerafterpreviouslyperformedunilateralnephrectomy AT evshutov comparisonoftwocombineddrugtherapyregimensforrenaldamageinpatientswithmetastatickidneycancerafterpreviouslyperformedunilateralnephrectomy AT sslebedev comparisonoftwocombineddrugtherapyregimensforrenaldamageinpatientswithmetastatickidneycancerafterpreviouslyperformedunilateralnephrectomy AT gmzapirov comparisonoftwocombineddrugtherapyregimensforrenaldamageinpatientswithmetastatickidneycancerafterpreviouslyperformedunilateralnephrectomy |